Applications are now closed!
The ALS Therapy Development Institute is proud to announce our Official Charity Partnership with the United Airlines NYC Half 2025. Team ALS TDI features runners from all over the globe with one universal mission, finding a cure for ALS. On Sunday, March 16, 2025, our runners will complete the 13.1-mile run through the streets of NYC to raise awareness for ALS TDI.
Your donations fuel our continuous efforts to advance promising drugs and help put a stop to this terrible disease. Please join in our fight to #ENDALS.
Runner Testimonial
“Running the New York City Marathon for ALS TDI was truly one of the most rewarding experiences that I have encountered since I started running marathons in search for a cure for ALS in 2012. The ALS TDI staff were so supportive and made me feel like part of the family. The supportive crowds on the streets of New York City made it a thrilling marathon to run. The New York City marathon is definitely an unbelievable experience and if I have the chance, I would love to do it again! Thank you, ALS TDI!”
- David McNeice
Benefits of Running the 2025 United Airlines
Half Marathon for Team ALS TDI
- Fundraising tips and assistance in the creation of a peer-to-peer web page for personal fundraising.
- Branded training and race apparel.
- Pre-race "carb load" dinner the night before the half marathon in NYC!
- Cheer zone along race course to keep runners motivated!
- Post race thank you gift!
ALS Therapy Development Institute
The ALS Therapy Development Institute (ALS TDI) is the world's foremost drug discovery lab focused solely on ALS. As a nonprofit biotech we operate without regard to profit or politics. Led by drug development experts and people with ALS, our Watertown, Massachusetts based lab is funded by a global network of supporters unified to end ALS. Our mission is to discover and develop effective treatments for ALS.
As the Drug Discover Engine for ALS, ALS TDI works to invent and discovers drugs until everyone with ALS has effective treatments. Our goal is to advance a new drug to clinical trial every two years. Learn more at www.als.net.